alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
39007.

#### WILLARD v. CITY OF EATONTON.

Fkankum, Judge.

The accused, T. G. Willard, was convicted in the Police Court of the City of Eatonton of the offense of speeding in violation of a municipal ordinance of said city. The undisputed facts show that the accused drove his motor vehicle in a motorcade through the City of Eatonton. After passing through the city, the motorcade was stopped' outside the city limits by the State Highway Patrol. Thereafter, city police officers arrived and gave each driver a “summons” to appear in the Police Court of Eatonton. A sharp conflict of evidence appears in the record as to whether the operators of the vehicles in the motorcade were speeding through the City of-Eatonton, but the evidence was sufficient to support a conviction of the defendant. After the accused was found guilty, he filed a petition for a writ of certiorari complaining that the charge against him should have been dismissed, in the police court for the reason that the act of the city officer who gave him a “summons” outside the City of Eatonton con*472stituted an illegal arrest. The petition for writ of certiorari was duly sanctioned; and thereafter, upon a hearing, the petition was overruled. This ruling is assigned as error in this appeal. *Held:*

Decided September 14, 1961

Rehearing denied September 28, 1961.

*James R. Venable,*for plaintiff in error.

*D. D. Veal,*contra.

“Courts of criminal jurisdiction not being required to inquire as to how the prisoner came into the reach of their mandates, the presence in the court of the defendant on a proper charge was sufficient to confer jurisdiction of his person, thereon.” *Nobles v. State,*81 Ga. App. 229 (58 SE2d 496).

"Whether one who arrested a person accused of the crime . . . was a lawful officer or not, or whether the arrest was legal or illegal, will not furnish any ground for acquitting the accused when brought to trial for such offense.” *Mitchell v.*State, 126 Ga. 84 (54 SE 931). To the same effect see *Joiner v. State,*66 Ga. App. 106 (17 SE2d 101); *Johnson v. Plunkett,*215 Ga. 353 (110 SE2d 745); *Reid v. Perkerson,*207 Ga. 27 (3) (60 SE2d 151); 22 C.J.S. 381, Criminal Law, § 144. Where a person appears voluntarily before a police court and enters a defense to a charge of speeding within the city limits in violation of a city ordinance, the fact that such person was served with a “summons” at a place outside the city limits by a city police officer will not serve as a ground to acquit the person so charged. Assuming, for the puipose of argument only, that the service of the “summons” on the accused by the city officer was an arrest and an illegal arrest, it cannot serve to acquit the accused under the above authorities. The untraversed answer of the trial judge to the writ of certiorari shows that the accused voluntarily appeared in court. This alone is enough to give the court jurisdiction of the person to try him for violation of a city ordinance perpetrated within the corporate city limits. The court did not err in overruling the petition for certiorari.

*Judgment affirmed.*

*Townsend, P. J., and Jordan, J., concur.*
Exhibit 21

                           Subsidiaries of Registrant


<TABLE>
<CAPTION>



                                            Percentage      Jurisdiction or
Subsidiary (1)                                Owned      State of Incorporation
------------------------------------------  ----------   ----------------------

Klamath First Federal Savings
<S>                                             <C>           <C>
  and Loan Association                          100%          United States

Klamath First Capital Trust I                   100%          Oregon

Klamath First Financial Services, Inc. (2)      100%          Oregon

Pacific Cascades Financial, Inc. (2)            100%          Oregon
<FN>


(1) The  operations  of the Company's  subsidiary  are included in the Company's
consolidated financial statements.

(2)   Wholly-owned   subsidiary  of  Klamath  First  Federal  Savings  and  Loan
Association
</FN>
</TABLE>
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

CARL SADLER,

Petitioner

v.

PHILADELPHIA COCA

- COLA (WORKERS' COMPENSATION APPEAL BOARD),

Respondent :

:

:

:

:

:

:

:

:

:

:

: No. 34 EAL 2022

Petition for Allowance of Appeal

from the Order of the

Commonwealth Court

ORDER

PER CURIAM

AND NOW , this 19th day of July, 2022

, the Petition for Allowance of Appeal is

DENIED

.
# C_2015065EN.01003301.xml

| 23.2.2015 | EN | Official Journal of the European Union | C 65/33 |
| --- | --- | --- | --- |

23.2.2015

EN

Official Journal of the European Union

C 65/33

---

Judgment of the General Court of 14 January 2015 — Melt Water v OHIM (MELT WATER Original)

(MELT WATER Original)

(Case T-69/14) (1)

1

((Community trade mark - Application for Community figurative mark MELT WATER Original - Absolute ground for refusal - Descriptive character - Article 7(1)(c) of Regulation (EC) No 207/2009))

(2015/C 065/46)

Language of the case: Lithuanian

Parties

Parties

Applicant: Research and Production Company ‘Melt Water’ UAB (Klaipėda, Lithuania) (represented by: V. Viešūnaitė, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: V. Melgar, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Fifth Board of Appeal of OHIM of 26 November 2013 (Case R 494/2013-5), concerning an application for registration of the figurative sign MELT WATER Original as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Research and Production Company ‘Melt Water’ UAB to pay the costs. |
| --- | --- |

2.

Orders Research and Production Company ‘Melt Water’ UAB to pay the costs.

---

(1)  OJ C 112, 14.4.2014.

1

---
# Table4

Table 4. Univariate statistics and percentiles of analytical results for soil samples collected in 2007, lower Rio Grande valley, Texas - Continued.		

Table 4. Univariate statistics and percentiles of analytical results for soil samples collected in 2007, lower Rio Grande valley, Texas.		

# Sheet2

# Sheet3
Exhibit 4.6

Schedule 1 to Exhibit 4.4  Individual Deviations from Standard MTIP 2004 Invitation Letter to  Members of the Management Board

|Name                                 |  | Maximum Incentive Amount (€)
for MTIP Tranche 2004 |  |                                                   
|------------------------------------ |  | -------------------------------------------------- |  | --------------------------------------------------
|Kai-Uwe Ricke                        |  | 750,000                                            |  |                                                   
|Dr. Karl-Gerhard Eick                |  | 562,500                                            |  |                                                   
|Dr. Heinz Klinkhammer                |  | 450,000                                            |  |                                                   
|René Obermann                        |  | 450,000                                            |  |                                                   
|Konrad F. Reiss (died April 6, 2005) |  | 200,000                                            |  | (participating pro rata, inclusive of April, 2005)
|Walter Raizner                       |  | 406,250                                            |  | (participating pro rata, starting Nov. 1, 2004)   

---

Maximum incentive amounts can only be reached if both 2004 plan targets are met. Amounts are payable in early 2007, according to the MTIP terms and conditions. Actual amounts
accrued for 2004 can be found in Item 6. See Exhibits 4.3 and 4.5 for further details.

---



QuickLinks
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM YOUBET.COM,
INCORPORATED FOR THE NINE MONTHS AND THREE MONTHS ENDED SEPTEMBER 30, 1999 AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   9-MOS                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999             DEC-31-1999
<PERIOD-START>                             JAN-01-1999             JUL-01-1999
<PERIOD-END>                               SEP-30-1999             SEP-30-1999
<CASH>                                      67,583,126              67,583,126
<SECURITIES>                                         0                       0
<RECEIVABLES>                                  340,646                 340,646
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                            70,411,638              70,411,638
<PP&E>                                       2,998,261               2,998,261
<DEPRECIATION>                             (1,134,073)             (1,134,073)
<TOTAL-ASSETS>                              73,913,917              73,913,917
<CURRENT-LIABILITIES>                        4,231,895               4,231,895
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                        19,121                  19,121
<OTHER-SE>                                  30,884,485              30,884,485
<TOTAL-LIABILITY-AND-EQUITY>                73,913,917              73,913,917
<SALES>                                      2,325,922               1,132,054
<TOTAL-REVENUES>                             2,325,922               1,132,054
<CGS>                                                0                       0
<TOTAL-COSTS>                               14,825,013               8,231,601
<OTHER-EXPENSES>                               825,710                 869,714
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                           2,038,201               1,014,213
<INCOME-PRETAX>                           (13,711,582)             (7,244,046)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                       (13,711,582)             (7,244,046)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                              (13,711,582)             (7,244,046)
<EPS-BASIC>                                      (.85)                   (.38)
<EPS-DILUTED>                                    (.85)                   (.38)


</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.2230 Chromatographic separation material for clinical use. ( a ) *Identification.* A chromatographic separation material for clinical use is a device accessory (e.g., ion exchange absorbents, ion exchagne resins, and ion papers) intended for use in ion exchange chromatography, a procedure in which a compound is separated from a solution.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 61 FR 1119, Jan. 16, 1996; 66 FR 38788, July 25, 2001]
§ 803.56 If I am a manufacturer, in what circumstances must I submit a supplemental or followup report and what are the requirements for such reports? If you are a manufacturer, when you obtain information required under this part that you did not provide because it was not known or was not available when you submitted the initial report, you must submit the supplemental information to us within 30 calendar days of the day that you receive this information. You must submit the supplemental or followup report in accordance with the requirements of § 803.12(a). On a supplemental or followup report, you must: ( a ) Indicate that the report being submitted is a supplemental or followup report;
( b ) Submit the appropriate identification numbers of the report that you are updating with the supplemental information (e.g., your original manufacturer report number and the user facility or importer report number of any report on which your report was based), if applicable; and
( c ) Include only the new, changed, or corrected information.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-START>                             APR-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                           6,933
<SECURITIES>                                         0
<RECEIVABLES>                                   48,827
<ALLOWANCES>                                         0
<INVENTORY>                                     39,055
<CURRENT-ASSETS>                                97,564
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 225,183
<CURRENT-LIABILITIES>                           69,889
<BONDS>                                              0
<COMMON>                                             0
<PREFERRED-MANDATORY>                           30,536
<PREFERRED>                                          0
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   225,183
<SALES>                                        100,427
<TOTAL-REVENUES>                               100,427
<CGS>                                           70,594
<TOTAL-COSTS>                                   88,612
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,963
<INCOME-PRETAX>                                  9,852
<INCOME-TAX>                                     3,448
<INCOME-CONTINUING>                              6,404
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     6,404
<EPS-PRIMARY>                                     1.01
<EPS-DILUTED>                                     1.01
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS WHICH ARE INCLUDED IN THE
REGISTRANT'S FORM 10-Q FOR THE PERIOD ENDED 9/30/00 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                        814241
<NAME>                       FORMICA CORPORATION
<MULTIPLIER>                                     1000
<CURRENCY>                                        $US

<S>                             <C>
<PERIOD-TYPE>                   9-mos
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   SEP-30-2000
<EXCHANGE-RATE>                                      1
<CASH>                                          10,000
<SECURITIES>                                         0
<RECEIVABLES>                                  131,400
<ALLOWANCES>                                     7,800
<INVENTORY>                                    152,600
<CURRENT-ASSETS>                               331,100
<PP&E>                                         506,700
<DEPRECIATION>                                 120,200
<TOTAL-ASSETS>                                 888,500
<CURRENT-LIABILITIES>                          178,000
<BONDS>                                        451,100
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           100
<OTHER-SE>                                      83,900
<TOTAL-LIABILITY-AND-EQUITY>                   888,500
<SALES>                                        554,500
<TOTAL-REVENUES>                               554,500
<CGS>                                          406,000
<TOTAL-COSTS>                                  407,900
<OTHER-EXPENSES>                               150,700
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              36,500
<INCOME-PRETAX>                                (36,700)
<INCOME-TAX>                                    (3,800)
<INCOME-CONTINUING>                            (40,500)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (40,500)
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
### C OURT OF 

### A PPEALS FOR THE



### F IRST 

### D ISTRICT OF 

### T EXAS AT 

### H OUSTON



### O RDER ON 

### M OTION

Cause Number: 01

- 14

- 0098 1

- CR

Trial Court Cause

Number: 1421328

Style: David James Chapman

v

. The State of Texas

Date motion filed * : July 14, 2015

Type of motion: Motion for extension of time to hold hearing

Party filing motion: Court

Document to be filed: Hearing record and supplemental clerk ’ s record

Is appeal accelerated? Yes No

If motion to extend time:

Original due date:

Number of previous extensions granted: 0

Date Requested: Addi tional 30 days to hold hearing as order e d on June 18, 2015 and to

return the requested records.

Ordered that motion is:

Granted

If document is to be filed, document due: 30 days after original deadline

Absent extraordinary circumstances, the Court will not grant additional motions to extend t ime

Denied

Dismissed ( e.g. , want of jurisdiction, moot)

Other:

Judge's signature: /s/ Harvey Brown

Acting individually Acting for the Court

Date: July 15, 2015
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Centers for Disease Control and Prevention

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

*Time and Date:*                         11 a.m.-5 p.m., April 22, 2010 (Closed).                    

*Place:*                         Teleconference.                    

*Status:*                         The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.                    

*Matters to be Discussed:*                         The meeting will include the initial review, discussion, and evaluation of applications received in response to “Public Health Research on Craniofacial Malformation, FOA DP 10-001.”                    

*Contact Person for More Information:*                         Michael Dalmat, DrPH, Scientific Review Officer, National Center for Chronic Disease and Health Promotion, Office of the Director, Extramural Research Program Office, 4770 Buford Highway, NE., Mailstop K-92, Atlanta, GA 30341, Telephone: (770) 488-6423, E-mail:                         *MED1@cdc.gov.*

                        The Director, Management Analysis and Services Office, has been delegated the authority to sign                         **Federal Register**                         notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.                    

Dated: February 24, 2010.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2010-4433 Filed 3-2-10; 8:45 am]

BILLING CODE 4163-18-P
§ 524.1044h Gentamicin, mometasone, and clotrimazole otic suspension. ( a ) *Specifications.* Each gram of suspension contains gentamicin sulfate, United States Pharmacopeia (USP) equivalent to 3 milligram (mg) gentamicin base, mometasone furoate monohydrate or mometasone furoate anhydrous, USP, equivalent to 1 mg mometasone, and 10 mg clotrimazole, USP.
( b ) *Sponsors.* See Nos. 000061 and 054925 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* For dogs weighing less than 30 pounds (lb), instill 4 drops from the 7.5-, 15-, or 30-gram (g) bottle into the ear canal (2 drops from the 215-g bottle) or, for dogs weighing 30 lb or more, instill 8 drops from the 7.5-, 15-, or 30-g bottle into the ear canal (4 drops from the 215-g bottle), once or twice daily for 7 days.
( 2 ) *Indications for use.* For the treatment of otitis externa caused by susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Pseudomonas* spp. [including *P. aeruginosa*], coagulase-positive staphylococci, *Enterococcus faecalis, Proteus mirabilis,* and beta-hemolytic streptococci).
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[66 FR 712, Jan. 4, 2001, as amended at 68 FR 15370, Mar. 31, 2003; 70 FR 36338, June 23, 2005; 79 FR 10969, Feb. 27, 2014; 81 FR 59134, Aug. 29, 2016]
#### § 820.86 Acceptance status.

Each manufacturer shall identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria. The identification of acceptance status shall be maintained throughout manufacturing, packaging, labeling, installation, and servicing of the product to ensure that only product which has passed the required acceptance activities is distributed, used, or installed.